Form 4100 R6.0: Cellular Therapy Essential Data Follow-Up Form

Center: CRID:

Key Fields

Sequence Number: _____

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number: _____

CIBMTR Research ID: _____

Event date: __ __ __ __ - __ __- __ __

Visit

○ 100 day ○ 6 months ○ 1 year ○ 2 years ○ > 2 years,

Specify: _____

Product

Questions: 1 - 1

1 Name of cellular therapy product *(for most recent cell therapy infusion)*

- ○ Axicabtagene ciloleucel (Yescarta®)
- ○ Brexucabtagene autoleucel (Tecartus™)
- ○ Ciltacabtagene autoleucel (JNJ-4528)
- ○ Idecabtagene vicleucel
- ○ Letetresgene autoleucel
- ○ Lisocabtagene maraleucel (Breyanzi™)
- ○ Orvacabtagene autoleucel
- ○ Tisagenlecleucel (Kymriah®)
- ○ Other product
- ○ No product name

Survival

Questions: 2 - 3

2 Date of actual contact with the recipient to determine medical status for this follow-up report: __ __ __ __ - __ __- __ __

3 Specify the recipient's survival status at the date of last contact

- ○ Alive **- Answers to subsequent questions should reflect clinical status since the date of last report**
- ○ Dead **- Answers to subsequent questions should reflect clinical status between the date of last report and immediately prior to death. Complete a Form 2900 - Recipient Death Data.**

Subsequent Cellular Infusions

Questions: 4 - 8

All additional cellular therapy infusions given for the same indication per protocol require a separate infusion form and should be reported on the Form 4000 for this course of cellular therapy. If a cellular therapy was administered for treatment of a different indication, or in response to disease progression / no response, a new Form 4000 (Pre-CTED) must be completed.

4 Has the recipient received a new course of cellular therapy (unplanned) since the date of last report?

○ Yes ○ No

5 Specify the reason for which cellular therapy was given

- ○ Failure to respond or in response to disease assessment
- ○ New indication

6 Date of cellular therapy: __ __ __ __ - __ __- __ __ **Also complete a Cellular Therapy Essential Data Pre-Infusion Form 4000**

7 Did the recipient receive an HCT since the date of last report?

- ○ Yes **- Also complete a Pre-TED Form 2400 for the subsequent HCT**
- ○ No

8 Date of HCT: __ __ __ __ - __ __- __ __

Best Response to Cellular Therapy

Questions: 9 - 11

9 What was the best response to the cellular therapy?

- ○ Continued complete response (CCR) *(for recipients in CR at the time of cellular therapy infusion)*
- ○ Complete response
- ○ Normalization of organ function
- ○ Partial response
- ○ Partial normalization of organ function
- ○ No response
- ○ Disease progression or worsening of organ function

10 Was the date of best response previously reported?

○ yes ○ no

11 Date response established: __ __ __ __ - __ __- __ __

Peripheral Blood Count Recovery

Questions: 12 - 20

12 Was there evidence of initial recovery?

- ○ Yes *(ANC ≥ 500/mm³ achieved and sustained for 3 lab values)*
- ○ No *(ANC ≥ 500/mm³ was not achieved)*
- ○ Not applicable *(ANC never dropped below 500/mm³ at any time after the start of lymphodepleting therapy / no lymphodepleting therapy given)*
- ○ Previously reported *(recipient's initial recovery was recorded on a previous report)*

13 Date ANC ≥ 500/mm3 *(first of 3 consecutive lab values)* __ __ __ __ - __ __- __ __

14 Following the initial recovery, was there subsequent decline in ANC to < 500/mm³ for ≥ 3 days since the date of last report?

○ yes ○ no

15 Date of decline in ANC to < 500/mm³ for ≥ 3 days: *(first of 3 days that the ANC declined)* __ __ __ __ - __ __- __ __

16 Did recipient recover and maintain ANC ≥ 500/mm³ following the decline?

○ yes ○ no

17 Date of ANC recovery

○ Known ○ Unknown

18 Date of ANC recovery: __ __ __ __ - __ __- __ __

19 Was an initial platelet count ≥ 20 x 10⁹/L achieved?

- ○ Yes
- ○ No
- ○ Not applicable *(platelet count never dropped below 20 x 10⁹/L at any time after the start of lymphodepleting therapy / no lymphodepleting therapy given)*
- ○ Previously reported *(≥ 20 x 10⁹/L was achieved and reported previously)*

20 Date platelets ≥ 20 x 10⁹/L: __ __ __ __ - __ __- __ __

Disease Relapse or Progression

Questions: 21 - 22

21 Was a disease relapse or progression detected since the date of last report?

○ yes ○ no

22 Date of relapse or progression: __ __ __ __ - __ __- __ __

Current Hematologic Findings

Questions: 23 - 33

23 Date of most recent complete blood count (CBC) sample drawn: __ __ __ __ - __ __- __ __

24 Complete blood count results available *(check all that apply)*

- ☐ WBC
- ☐ Neutrophils
- ☐ Lymphocytes
- ☐ Hemoglobin
- ☐ Hematocrit
- ☐ Platelets

25 WBC: _____ ○ x 10⁹/L (x 10³/mm³) ○ x 10⁶/L

26 Neutrophils: _____ %

27 Lymphocytes: _____ %

28 Hemoglobin: _____ ○ g/dL ○ g/L ○ mmol/L

29 Hematocrit: _____ %

30 Were RBCs transfused ≤ 30 days before the date the sample was drawn?

○ Yes ○ No

31 Platelets: _____ ○ x 10⁹/L (x 10³/mm³) ○ x 10⁶/L

32 Were platelets transfused ≤ 7 days before the date the sample was drawn?

○ Yes ○ No

33 Did the recipient receive any growth factors ≤ 7 days before the date the sample was drawn?

○ Yes ○ No

New Malignancy, Lymphoproliferative or Myeloproliferative Disease / Disorder

Questions: 34 - 34

Report new malignancies that are different than the indicated disease / disorder for which this cellular therapy was performed. Do NOT include relapse, progression or transformation of the same disease subtype.

34 Did a new malignancy, myelodysplastic, myeloproliferative, or lymphoproliferative disease / disorder occur that is different from the disease / disorder for which the infusion was performed? *(include clonal cytogenetic abnormalities, and post-transplant lymphoproliferative disorders)*

- ○ Yes **- Also complete Subsequent Neoplasms Form 3500**
- ○ No
- ○ Previously reported *(form 3500 has already been submitted for this event)*

Persistence of Cells

Questions: 35 - 59

This section pertains to the evaluation of persistence of a cellular product in the recipient.

35 Were tests performed to detect persistence of the cellular product since the date of last report?
○ Yes ○ No

36 Was persistence evaluated by molecular assay? *(e.g. PCR)*
○ Yes ○ No

37 Date sample collected: __ __ __ __ - __ __- __ __

38 Specify the cell source *(check all that apply)*
- ☐ Bone marrow
- ☐ Peripheral blood
- ☐ Tumor
- ☐ Other source

39 Specify other cell source: _____

40 Were the infused cells detected?
○ Yes ○ No

41 Was persistence evaluated by flow cytometry testing? *(immunophenotyping)*
○ Yes ○ No

42 Date sample collected: __ __ __ __ - __ __- __ __

43 Specify the cell source *(check all that apply)*
- ☐ Bone marrow
- ☐ Peripheral blood
- ☐ Tumor
- ☐ Other source

44 Specify other cell source: _____

45 Were the infused cells detected?
○ Yes ○ No

46 Were B-cell counts monitored after infusion?
○ Yes ○ No

47 Was there B-cell recovery?
○ Yes ○ No

48 Date of B-cell recovery: __ __ __ __ - __ __- __ __

49 Was persistence evaluated by immunohistochemistry?
○ Yes ○ No

50 Date sample collected: __ __ __ __ - __ __- __ __

51 Specify the cell source *(check all that apply)*
- ☐ Bone marrow
- ☐ Peripheral blood
- ☐ Tumor
- ☐ Other source

52 Specify other cell source: _____

53 Were the infused cells detected?
○ Yes ○ No

54 Was persistence evaluated by another method?
○ Yes ○ No

55 Specify other method: _____

56 Date sample collected: __ __ __ __ - __ __- __ __

57 Specify the cell source *(check all that apply)*
- ☐ Bone marrow
- ☐ Peripheral blood
- ☐ Tumor
- ☐ Other source

58 Specify other cell source: _____

59 Were the infused cells detected?
○ Yes ○ No

Graft vs. Host Disease

Questions: 60 - 79

This section is for allogeneic infusions only. If this was an autologous infusion, continue to the "Toxicities" section.

60 Did acute GVHD develop since the date of last report?

○ Yes ○ No ○ Unknown

61 Date of acute GVHD diagnosis: __ __ __ __ - __ __- __ __

62 Did acute GVHD persist since the date of last report?

○ Yes ○ No ○ Unknown

63 Overall grade of acute GVHD at diagnosis

- ○ I - Rash on ≤ 50% of skin, no liver or gut involvement
- ○ II - Rash on > 50% of skin, bilirubin 2-3 mg/dL, or diarrhea 500-1000 mL/day or persistent nausea or vomiting
- ○ III - Bilirubin 3-15 mg/dL, or gut stage 2-4, diarrhea >1000 mL/day or severe abdominal pain with or without ileus
- ○ IV - Generalized erythroderma with bullous formation, or bilirubin >15 mg/dL
- ○ Not applicable (acute GVHD present but grade is not applicable)

List the stage for each organ at diagnosis of acute GVHD:

64 Skin

- ○ Stage 0 - No rash, no rash attributable to acute GVHD
- ○ Stage 1 - Maculopapular rash, < 25% of body surface
- ○ Stage 2 - Maculopapular rash, 25-50% of body surface
- ○ Stage 3 - Generalized erythroderma, > 50% of body surface
- ○ Stage 4 - Generalized erythroderma with bullae formation and/or desquamation

65 Lower intestinal tract *(use mL/day for adult recipients and mL/kg/day for pediatric recipients)*

- ○ Stage 0 - No diarrhea, no diarrhea attributable to acute GVHD / diarrhea < 500 mL/day (adult), or < 10 mL/kg/day (pediatric)
- ○ Stage 1 - Diarrhea 500-1000 mL/day (adult), or 10-19.9 mL/kg/day (pediatric)
- ○ Stage 2 - Diarrhea 1001-1500 mL/day (adult), or 20-30 mL/kg/day (pediatric)
- ○ Stage 3 - Diarrhea > 1500 mL/day (adult), or > 30 mL/kg/day (pediatric)
- ○ Stage 4 - Severe abdominal pain, with or without ileus, and/or grossly bloody stool

66 Upper intestinal tract

- ○ Stage 0 - No persistent nausea or vomiting
- ○ Stage 1 - Persistent nausea or vomiting

67 Liver

- ○ Stage 0 - No liver acute GVHD / bilirubin < 2.0 mg/dL (< 34 µmol/L)
- ○ Stage 1 - Bilirubin 2.0-3.0 mg/dL (34-52 µmol/L)
- ○ Stage 2 - Bilirubin 3.1-6.0 mg/dL (53-103 µmol/L)
- ○ Stage 3 - Bilirubin 6.1-15.0 mg/dL (104-256 µmol/L)
- ○ Stage 4 - Bilirubin >15.0 mg/dL (> 256 µmol/L)

68 Other site(s) involved with acute GVHD

○ Yes ○ No

69 Specify other site(s): _____

Specify the MAXIMUM overall grade of acute GVHD since the date of last report:

70 Maximum overall grade of acute GVHD

- ○ I - Rash on ≤ 50% of skin, no liver or gut involvement
- ○ II - Rash on > 50% of skin, bilirubin 2-3 mg/dL, or diarrhea 500-1000 mL/day or persistent nausea or vomiting
- ○ III - Bilirubin 3-15 mg/dL, or gut stage 2-4 diarrhea > 1000 mL/day or severe abdominal pain with or without ileus
- ○ IV - Generalized erythroderma with bullous formation, or billirubin > 15 mg/dL
- ○ Not applicable (acute GVHD present but grade is not applicable)

71 Date maximum overall grade of acute GVHD: __ __ __ __ - __ __- __ __

72 Did chronic GVHD develop since the date of last report?

○ Yes ○ No ○ Unknown

73 Date of chronic GVHD diagnosis: __ __ __ __ - __ __- __ __ ☐ Date estimated

74 Did chronic GVHD persist since the date of last report?

○ Yes ○ No ○ Unknown

Specify the MAXIMUM grade of chronic GVHD since the date of last report:

75 Maximum grade of chronic GVHD *(according to best clinical judgment)*

○ Mild ○ Moderate ○ Severe ○ Unknown

76 Specify if chronic GVHD was limited or extensive

- ○ Limited - Localized skin involvement and/or liver dysfunction
- ○ Extensive - One or more of the following:
  - *Generalized skin involvement; or,*
  - *Liver histology showing chronic aggressive hepatitis, bridging necrosis or cirrhosis; or,*
  - *Involvement of eye: Schirmer's test with < 5 mm wetting; or*
  - *Involvement of minor salivary glands or oral mucosa demonstrated on labial biopsy; or*
  - *Involvement of any other target organ*

77 Date of maximum grade of chronic GVHD: __ __ __ __ - __ __- __ __

78 Is the recipient still taking systemic steroids? *(Do not report steroids for adrenal insufficiency, ≤ 10 mg/day for adults, < 0.1 mg/kg/day for children)*

○ Yes ○ No ○ Not Applicable ○ Unknown

79 Is the recipient still taking (non-steroid) immunosuppressive agents (including PUVA) for GVHD?

○ Yes ○ No ○ Not Applicable ○ Unknown

Toxicities

Questions: 80 - 170

Cytokine Release Syndrome (CRS)

80 Did the recipient experience Cytokine Release Syndrome (CRS)?

○ Yes ○ No

81 Was the date of diagnosis previously reported?

○ Yes ○ No

82 Date of CRS diagnosis: __ __ __ __ - __ __- __ __

83 Specify therapy given for CRS *(check all that apply)*

- ☐ Anakinra
- ☐ Corticosteroids
- ☐ Siltuximab
- ☐ Tocilizumab
- ☐ Other therapy
- ☐ No therapy given

84 Specify other therapy: _____

85 Doses of tocilizumab given

○ 1 ○ ≥ 2

86 Indicate the symptoms of CRS *(check all that apply)*

- ☐ Fevers *(> 100.4 F or > 38 C)*
- ☐ Hypotension requiring therapy
- ☐ Hypoxia requiring minimal supplemental oxygen *(FiO2 < 40%)*
- ☐ Hypoxia requiring more than minimal supplemental oxygen *(FiO2 ≥ 40%)*
- ☐ Unknown

87 Date of fever onset: __ __ __ __ - __ __- __ __

88 Date of hypotension onset: __ __ __ __ - __ __- __ __

89 Specify therapy given for hypotension *(check all that apply)*

- ☐ Intravenous fluids
- ☐ Vasopressor(s)
- ☐ Other

90 Specify other therapy: _____

91 Specify the number of vasopressors used for therapy

○ 1 ○ ≥2

92 Specify the vasopressor(s) used *(check all that apply)*

- ☐ Phenylephrine
- ☐ Norepinephrine
- ☐ Epinephrine
- ☐ Dopamine
- ☐ Vasopressin
- ☐ Other

93 Specify other vasopressor: _____

94 Was hypotension controlled with therapy?

○ Yes ○ No ○ Unknown

95 Date of hypoxia onset for minimal supplemental oxygen: *(FiO2 < 40%)* __ __ __ __ - __ __- __ __

96 Date of hypoxia onset for more than minimal supplemental oxygen: *(FiO2 ≥ 40%)* __ __ __ __ - __ __- __ __

97 Was positive pressure ventilatory support required? *(CPAP, BiPAP, intubation and mechanical ventilation)*

○ Yes ○ No ○ Unknown

98 Date started: __ __ __ __ - __ __- __ __

99 Were there features related to macrophage activation syndrome (MAS) / hemophagocytic lymphohistiocytosis (HLH)?

○ Yes ○ No

100 Date of MAS / HLH onset: __ __ __ __ - __ __- __ __

101 Did the recipient have splenomegaly?

○ yes ○ no

102 Was MAS / HLH confirmed by a bone marrow biopsy?

○ Yes ○ No

103 Specify the laboratory values collected *(check all that apply)*

☐ Fibrinogen

☐ Triglyceride

☐ None

104 Lowest fibrinogen level: _____ ○ mg/dL ○ mg/L

105 Date fibrinogen sample collected: __ __ __ __ - __ __- __ __

106 Highest triglyceride level: _____ ○ mg/dL ○ mmol/L

107 Date triglyceride sample collected: __ __ __ __ - __ __- __ __

108 Did cytokine release syndrome resolve?

○ Yes ○ No

109 Date resolved: __ __ __ __ - __ __- __ __

Neurotoxicity (ICANS)

110 Did the recipient experience neurotoxicity (ICANS)?

○ Yes ○ No

111 Was the date of onset previously reported?

○ Yes ○ No

112 Date of neurotoxicity (ICANS) onset: __ __ __ __ - __ __- __ __

113 Specify therapy given for neurotoxicity *(check all that apply)*

☐ Anti-epileptics

☐ Anakinra

☐ Corticosteroids

☐ Siltuximab

☐ Tocilizumab

☐ Other therapy

☐ No therapy given

114 Specify other therapy: _____

115 Which cognitive assessment was performed?

○ CARTOX ○ ICE ○ None

116 What was the lowest score?

○ 10

○ 9

○ 8

○ 7

○ 6

○ 5

○ 4

○ 3

○ 2

○ 1

○ 0

○ Unable to complete assessment

For symptoms of neurotoxicity (ICANS), report the HIGHEST grade observed in this reporting period

117 Indicate the symptoms of neurotoxicity (ICANS) *(check all that apply)*

- ☐ Aphasia *(speech impairment resulting in full loss of language)*
- ☐ Cerebral edema
- ☐ Cerebrovascular accident *(stroke)*
- ☐ Depressed level of consciousness
- ☐ Dysphasia *(speech impairment resulting in partial loss of language)*
- ☐ Hallucinations
- ☐ Hemiparesis / paraparesis / other motor deficit
- ☐ Leukoencephalopathy
- ☐ Seizure
- ☐ Tremors
- ☐ Other symptom

118 Specify other symptom: _____

119 Specify type of cerebral edema

- ○ Focal / local edema on neuroimaging
- ○ Diffuse cerebral edema on neuroimaging; decerebrate or decorticate posturing; or cranial nerve VI palsy; or papilledema; or Cushing's triad

120 Date of cerebrovascular accident onset: __ __ __ __ - __ __- __ __

121 Specify type of cerebrovascular accident

○ Hemorrhagic ○ Ischemic

122 Specify the most severe level of depressed level of consciousness

- ○ Awakens spontaneously
- ○ Awakens to voice
- ○ Awakens only to tactile stimulus
- ○ Patient unarousable or requires vigorous or repetitive tactile stimuli to arouse; stupor or coma

123 Specify the grade of dysphasia

- ○ 1 *(awareness of receptive or expressive characteristics; not impairing ability to communicate)*
- ○ 2 *(moderate receptive or expressive characteristics; impairing ability to communicate spontaneously)*

124 Specify the type of seizure

- ○ Complex partial
- ○ Generalized tonic-clonic
- ○ Non-convulsive status epilepticus
- ○ Simple partial
- ○ Status epilepticus
- ○ Other type
- ○ Unknown

125 Specify other type: _____

126 Specify the severity of the seizure

- ○ Grade 3 *(any clinical seizure focal or generalized that resolves rapidly; or non-convulsive seizures on EEG that resolve with intervention)*
- ○ Grade 4 *(life-threatening prolonged seizure that is > 5 min; or repetitive clinical or electrical seizures without return to baseline in between)*

127 Did neurotoxicity (ICANS) resolve?

○ Yes ○ No

128 Date resolved: __ __ __ __ - __ __- __ __

Other toxicities

129 Hypogammaglobulinemia

○ Yes ○ No ○ Unknown

130 Was the date of onset previously reported?

○ Yes ○ No

131 Date of onset: __ __ __ __ - __ __- __ __

132 Did hypogammaglobulinema resolve?

○ Yes ○ No

133 Date resolved: __ __ __ __ - __ __- __ __

134 Did recipient require immunoglobulin replacement therapy?

○ Yes ○ No

135 Is the recipient still requiring replacement therapy?

○ Yes ○ No

136 Tumor lysis syndrome
○ Yes ○ No ○ Unknown

137 Was the date of onset previously reported?
○ Yes ○ No

138 Date of onset: __ __ __ __ - __ __- __ __

139 Grade
○ 3 ○ 4 ○ 5

140 Did tumor lysis syndrome resolve?
○ Yes ○ No

141 Date resolved: __ __ __ __ - __ __- __ __

142 Other toxicity
○ Yes ○ No ○ Unknown

Other Toxicities (1) **Questions: 143 - 147**

143 Specify other toxicity: _____

144 Was the date of onset previously reported?
○ Yes ○ No

145 Date of onset: __ __ __ __ - __ __- __ __

146 Did other toxicity resolve?
○ Yes ○ No

147 Date resolved: __ __ __ __ - __ __- __ __

Specify if the recipient has experienced any of the following since the date of last report:

148 Has the recipient experienced a grade 3 organ toxicity?
○ Yes ○ No ○ Unknown

Grade 3 Toxicities (1) **Questions: 149 - 154**

149 Specify organ
○ Cardiovascular ○ Gastrointenstinal ○ Kidneys ○ Liver ○ Lungs ○ Musculoskeletal ○ Nervous system ○ Other

150 Specify the toxicity _____

151 Was the date of onset previously reported?
○ Yes ○ No

152 Date of onset: __ __ __ __ - __ __- __ __

153 Did the grade 3 toxicity resolve?
○ Yes ○ No

154 Date resolved __ __ __ __ - __ __- __ __

155 Has the recipient experienced a grade 4 organ toxicity?
○ Yes ○ No ○ Unknown

Grade 4 Toxicities (1) **Questions: 156 - 161**

156 Specify organ
○ Cardiovascular ○ Gastrointenstinal ○ Kidneys ○ Liver ○ Lungs ○ Musculoskeletal ○ Nervous system ○ Other

157 Specify the toxicity _____

158 Was the date of onset previously reported?
○ Yes ○ No

159 Date of onset: __ __ __ __ - __ __- __ __

160 Did the grade 4 toxicity resolve?
○ Yes ○ No

161 Date resolved: __ __ __ __ - __ __- __ __

162 Specify the laboratory values collected *(check all that apply)*

- ☐ C-reactive protein
- ☐ Interleukin-6
- ☐ Soluble interleukin-2 receptor α *(sIL2RA or soluble CD25)*
- ☐ Total serum ferritin
- ☐ None

Specify the MAXIMUM lab results since the date of last report:

163 Maximum C-reactive protein: _____ ○ mg/dL ○ mg/L

164 Date C-reactive protein collected: __ __ __ __ - __ __- __ __

165 Maximum interleukin-6: _____ ○ pg/mL ○ IU/mL

166 Date Interleukin-6 collected: __ __ __ __ - __ __- __ __

167 Maximum soluble interleukin-2 receptor α: _____ ○ pg/mL ○ IU/mL ○ U/mL

168 Date soluble interleukin-2 receptor α collected: __ __ __ __ - __ __- __ __

169 Maximum total serum ferritin: _____ ng/mL (µg/L)

170 Date serum ferritin collected: __ __ __ __ - __ __- __ __

Infection — Questions: 171 - 175

171 Did the recipient develop a clinically significant infection since the date of last report?

○ Yes ○ No

Infection (1) — Questions: 172 - 175

Report each infection organism, site, and date of diagnosis

172 Organism _____

173 Specify other organism: _____

174 Site *(check all that apply)*

- ☐ Blood
- ☐ Bone
- ☐ CNS
- ☐ Eyes
- ☐ Genital area
- ☐ GI tract, Lower
- ☐ GI tract, Upper
- ☐ Joints
- ☐ Liver/Spleen
- ☐ Lung
- ☐ Sinus and/or Upper respiratory tract
- ☐ Skin, cellulitis
- ☐ Skin, necrotizing fasciitis
- ☐ Urinary tract, Lower
- ☐ Urinary tract, Upper

175 Date of diagnosis: __ __ __ __ - __ __- __ __

Pregnancy Status — Questions: 176 - 177

176 Was the recipient pregnant at any time in this reporting period? **(Female only)**

- ○ Yes **- Also complete Pregnancy Form 3501**
- ○ No
- ○ Unknown
- ○ Previously reported *(form 3501 already submitted for this event)*

177 Was the recipient's female partner pregnant at any time in this reporting period? **(Male only)**

- ○ Yes **- Also complete Pregnancy Form 3501**
- ○ No
- ○ Unknown
- ○ Previously reported *(form 3501 already submitted for this event)*

First Name: _____

Last Name: _____

E-mail address: _____

Center: CRID:

Date: __ __ __ __ - __ __ - __ __